Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

References

• ConnollySJEzekowitzMDYusufSReillyPAWallentinLNewly identified events in the RE-LY trialN Engl J Med2010363191875187621047252
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• OlssonSBStroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialLancet200336293971691169814643116
   PubMed Web of Science ®Google Scholar
• AlbersGWDienerHCFrisonLXimelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trialJAMA2005293669069815701910
   PubMed Web of Science ®Google Scholar
• ConnollySPogueJHartRClopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialLancet200636795261903191216765759
   PubMed Web of Science ®Google Scholar
• MantJHobbsFDFletcherKWarfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trialLancet2007370958649350317693178
   PubMed Web of Science ®Google Scholar
• BousserMGBouthierJBullerHRComparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trialLancet2008371960931532118294998
   PubMed Web of Science ®Google Scholar
• ConnollySJPogueJHartRGEffect of clopidogrel added to aspirin in patients with atrial fibrillationN Engl J Med2009360202066207819336502
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialCirculation2012125566967622215856
   PubMed Web of Science ®Google Scholar
• ErikssonBISmithJJCapriniJEvaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trialsThromb Res2012130339640222704461
   PubMed Web of Science ®Google Scholar
• CorreiaLCLopesAADabigatran and myocardial infarction: meta-illusion?Arch Intern Med20121721082322636828
   PubMedGoogle Scholar
• LipGYLaneDADoes warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?Am J Med2010123978578920655037
   PubMed Web of Science ®Google Scholar
• UchinoKHernandezAVDabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med2012172539740222231617
   PubMed Web of Science ®Google Scholar
• JacobsJMStessmanJDabigatran: do we have sufficient data?: comment on “Dabigatran association with higher risk of acute coronary events”Arch Intern Med2012172540340422231616
   PubMedGoogle Scholar
• WallentinLWilcoxRGWeaverWDOral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trialLancet2003362938678979713678873
   PubMed Web of Science ®Google Scholar
• LipGYRasmussenLHOlssonSBOral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs vitamin K antagonistsEur Heart J200930232897290719690349
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEBullerHRA new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJ Thromb Haemost20053110311115634273
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb Haemost20075112178218517764540
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialLancet2007370959194995617869635
   PubMed Web of Science ®Google Scholar
• GinsbergJSDavidsonBLCompPCOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgeryJ Arthroplasty20092411918534438
   PubMed Web of Science ®Google Scholar
• FujiTFuijitaSUjihiraTSatoTDabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placeboJ Arthroplasty20102581267127419854610
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEHuoMHOral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trialThromb Haemost2011105472172921225098
   PubMed Web of Science ®Google Scholar
• EzekowitzMDReillyPANehmizGDabigatran with or without concomitant aspirin compared with warfarin alone in patients with non-valvular atrial fibrillation (PETRO Study)Am J Cardiol200710091419142617950801
   PubMed Web of Science ®Google Scholar
• TomimoriHYamamuraNAdachiTOpen label, randomized exploratory, dose response study of the pharmacodynamics and safety of BIBR 1148 (110 mg bid and 150 mg bid) for 12 weeks in patients with non-valvualr atrial fibrillation in comparison to warfarin2007Study Number 1160.49. Report number U07-3126. Boehringer Ingelheim Internal Report
   Google Scholar
• SchulmanSErikssonHGoldhaberSZDabigatran or warfarin for extended maintenance therapy of venous thromboembolism (abstract O-TH-033)J Thromb Haemost20119Suppl 2731732
   Google Scholar
• SchulmanSBaanstraDErikssonHDabigatran versus placebo for extended maintenance therapy of venous thromboembolism (abstract O-MO-037)J Thromb Haemost20119Suppl 222
   Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKSchellongSA randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II)ASH Annual Meeting Abstracts2011118A205
   Google Scholar
• OldgrenJBudajAGrangerCBDabigatran versus placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trialEur Heart J201132222781278921551462
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOEAhnfeltLDose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJ Thromb Haemost2004291573158015333033
   PubMed Web of Science ®Google Scholar
• PETRO-EX InvestigatorsSafety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillationCerebrovasc Dis200621Suppl 42
   Google Scholar
• RothbergMBCelestinCFioreLDLawlerECookJRWarfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefitAnn Intern Med2005143424125016103468
   PubMed Web of Science ®Google Scholar
• RoskellNSLipGYNoackHClemensAPlumbJMTreatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilateThromb Haemost201010461106111520967400
   PubMed Web of Science ®Google Scholar
• Johnson and JohnsonSlides for the September 8, 2011 Meeting of the Cardiovascular and Renal Drugs Advisory Committee, slide No 129 and 1532011
   Google Scholar
• BüllerHRDécoususHGrossoMAEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med912013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• LopesRDStarrAPieperCFWarfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromesAm J Med2010123213414020103022
   PubMed Web of Science ®Google Scholar
• HurlenMAbdelnoorMSmithPErikssenJArnesenHWarfarin, aspirin, or both after myocardial infarctionN Engl J Med20023471396997412324552
   PubMed Web of Science ®Google Scholar
• AndreottiFTestaLBiondi-ZoccaiGGCreaFAspirin plus warfarin compared with aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patientsEur Heart J200627551952616143706
   PubMed Web of Science ®Google Scholar
• BreithartGBaumgartnerHBerkowitzSDCharacteristics and outcomes of patients with atrial fibrillation and significant valvular lesions experience from the ROCKET AF trialJ Am Coll Cardiol201361Suppl 10E282
   PubMed Web of Science ®Google Scholar
• KadoglouNPMoustardasPKatsimpoulasMThe beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosisCardiovasc Drugs Ther201226536737422940777
   PubMed Web of Science ®Google Scholar
• LeeIOKratzMTSchirmerSHBaumhakelMBohmMThe effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient miceJ Pharmacol Exp Ther2012343225325722837011
   PubMed Web of Science ®Google Scholar
• PreuschMWijelathESMurrayJDabigatran etexilate, a new oral thrombin inhibitor, retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient miceArterioscl Thromb Vasc Biol201030E185
   Web of Science ®Google Scholar
• van RynJDietzTKuritschIEffect of direct thrombin inhibitor, dabigatran, on arterial thrombosis when given in combination with aspirin (ASA) in a cyclic flow model of anaesthesised pigs (abstract PP_MO-347)J Thromb Haemost20097Suppl 2435
   Google Scholar
• ConnollySJWallentinLEzekowitzMDThe Long Term Multi-Center Observational Study of Dabigatran Treatment in Patients with Atrial Fibrillation: (RELY-ABLE) StudyCirculationJune142013 [Epub ahead of print.]
   Google Scholar
• Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. Direct Thrombin Inhibitor Trialists’ Collaborative GroupAm Heart J20011411E211136505
   PubMedGoogle Scholar
• StoneGWWitzenbichlerBGuagliumiGBivalirudin during primary PCI in acute myocardial infarctionN Engl J Med2008358212218223018499566
   PubMed Web of Science ®Google Scholar
• StoneGWWitzenbichlerBGuagliumiGHeparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trialLancet201137797842193220421665265
   PubMed Web of Science ®Google Scholar
• DienerHCStroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studiesCerebrovasc Dis200621427929316449807
   PubMed Web of Science ®Google Scholar